Last reviewed · How we verify
Anti-IL23
IL-23 inhibitor
IL-23 inhibitor Used for Psoriasis, Crohn's disease, Ulcerative colitis.
At a glance
| Generic name | Anti-IL23 |
|---|---|
| Sponsor | Prof. Dr. Stephan Weidinger |
| Drug class | Biologic |
| Target | IL-23 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
IL-23 is a pro-inflammatory cytokine involved in the pathogenesis of various autoimmune and inflammatory diseases. Inhibiting IL-23 has been shown to reduce inflammation and modulate the immune response.
Approved indications
- Psoriasis
- Crohn's disease
- Ulcerative colitis
Common side effects
- Headache
- Nausea
- Fatigue
Key clinical trials
- Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
- A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis (PHASE2)
- Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
- Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant (PHASE2)
- High Dose Risankizumab for Psoriasis (PHASE2)
- Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease (PHASE3)
- COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)
- Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |